

REMARKS

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Previously Presented) A method for reduction of adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment, and wherein the administration of the substance that inhibits a pro-inflammatory cytokine causes a reduction of adhesion formation.
2. (Original) The method of claim 1, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF.
3. (Original) The method of claim 1, wherein said pro-inflammatory cytokine is selected from the group consisting of TNF and IL-1.
4. (Original) The method of claim 1, for treatment of post-traumatic tissue injury.
5. (Original) The method of claim 4, wherein said post-traumatic tissue injury is caused by surgery.
6. (Original) The method of claim 1, for treatment of a thermic injury.
7. (Original) The method of claim 1, for treatment of a pathological condition with scar formation.

8. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by a vascular disease selected from the group consisting of bleeding and infarct.

9. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by a toxic influence.

10. (Original) The method of claim 7, wherein said pathological condition with scar formation is caused by cystic fibrosis.

11. - 22. (Canceled).

23. (Currently Amended) The method of claim 1, wherein said substance is ~~lactoferrin or~~ a peptide derived from lactoferrin.

24. (Original) The method of claim 1, wherein said substance is locally administered.

25. (Original) The method of claim 1, wherein said substance is systemically administered.

26. (New) A method for reduction of adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment, and wherein the administration of the substance that inhibits a pro-inflammatory cytokine causes a reduction of adhesion formation, wherein the post-traumatic tissue injury is caused by surgery.

27. (New) A method for reduction of adhesion formation wherein a therapeutically effective amount of a substance that inhibits a pro-inflammatory cytokine is administered to a patient in need of said treatment, and wherein the administration of the substance that inhibits a pro-inflammatory cytokine causes a

reduction of adhesion formation, wherein the post-traumatic tissue injury is caused by surgery, and wherein the pro-inflammatory cytokine is selected from the group consisting of TNF, IL-1, IL-6, IL-8, IL-12, IL-15, IL-17, IL-18, GM-CSF, M-CSF, MCP-1, MIP-1, RANTES, ENA-78, OSM, FGF, PDGF, and VEGF.